Original Source(s)
Related Content
FDA approves first therapy for warm autoimmune hemolytic anemia
The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.
August 25, 2026
-
3 min
FDA approves XFG-adapted COVID-19 vaccine
The 2026 to 2027 formulation aligns with FDA guidance on the preferred composition for COVID-19 vaccines beginning this fall.
August 28, 2026
-
2 min